

**Fig. S1.** Optimal selection of experimental reaction conditions. (A) Selection of PLA2R antigen coating concentration. (B) Optimization of the optimal concentration of mouse anti-human IgG antibody. (C) Selection of the optimal dilution ratio in the specific and non-specific binding (NSB) curve of  $\text{Eu}^{3+}$ - goat anti-mouse IgG antibody. (D) Detection range screening for optimal linear range. (E) Linear curve of the ultrasensitive PLA2R-IgG-TRFIA assay.

**Table S1.**


Precision of ultrasensitive PLA2R-IgG-TRFIA.

Standard concentration (RU/mL)	Intra-assay Precision CV (%)	Inter-assay Precision CV (%)
5.3	5.76	9.19
14.5	3.16	6.36
245.0	3.38	4.39
Average	4.10	6.65


**Table S2.**

Ultrasensitive PLA2R-IgG TRFIA recovery test results ( $n=3$ )

Concentration of standard (RU/mL)	Original Concentration (RU/mL)	Theoretical Concentration (RU/mL)	Measured Concentration (RU/mL)	Recovery (%)
245.00	56.81	75.63	72.21	95.48
			81.33	107.54
			73.56	97.26



**Fig.S2.** Correlation of ultrasensitive PLA2R-IgG-TRFIA with ELISA values in PMN patients.



**Fig.S3 .** ROC curves of anti-PLA2R IgG levels between HC 、 DC and PMN patients